AstraZeneca applies artificial intelligence and data science to pharmaceutical research and development, working alongside precision medicine, cell therapies, and small-molecule and biopharmaceutical drug discovery. The company, formed in 1999 through the merger of Astra AB and Zeneca Group PLC, discovers, develops and commercialises therapies across oncology, biopharmaceuticals, respiratory and rare diseases.
Its pipeline stands at 197 projects, with 20 new medicines targeted by 2030 and 16 blockbuster medicines already on the market. Billions are invested annually in research and development across six strategic R&D centres.
Research operations are concentrated in the United Kingdom and Sweden, with further sites in the United States and China; named locations include Cambridge (UK), Gothenburg, Gaithersburg, Boston, Shanghai and Beijing. The company describes its approach as following the science and putting patients first, with an emphasis on next-generation therapeutics and transforming patient outcomes.
